Multiple Sclerosis Clinical Trials in Chicago, IL

36 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis	Phase 3	Sanofi	2 mi
Effects of High-intensity Gait Training on Fatigue, Gait, and Neuroplasticity in People With Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Study of COYA 302 for the Treatment of ALS	Phase 2	Coya Therapeutics	2 mi
TSC Biosample Repository and Natural History Database	—	National Tuberous Sclerosis Association	2 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)	—	TG Therapeutics, Inc.	2 mi
Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis	—	Shirley Ryan AbilityLab	2 mi
Intermittent Hypoxia in Persons With Multiple Sclerosis	N/A	Shirley Ryan AbilityLab	2 mi
Nomad P-KAFO Study	N/A	Shirley Ryan AbilityLab	2 mi
Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain	N/A	Shirley Ryan AbilityLab	2 mi
Remote Therapeutic Monitoring Exercise Tracking	N/A	Shirley Ryan AbilityLab	2 mi
Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.	Phase 3	Novartis Pharmaceuticals	2 mi
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis	Phase 4	Northwestern University	2 mi
Functional Balance Intervention in Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
A Study of AZD0120 in Autoimmune Diseases	Phase 1	AstraZeneca	2 mi
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis	Phase 4	National Institute of Allergy and Infectious Diseases (NIAID)	2 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab	Phase 3	TG Therapeutics, Inc.	2 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study	Phase 2	Darcy Krueger	2 mi
Home Based Functional Balance Intervention for Multiple Sclerosis	N/A	University of Illinois at Chicago	2 mi
Exercise Rehabilitation Program in MS Who Use Wheelchairs as a Primary Mobility Device	N/A	University of Illinois at Chicago	2 mi
Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS	N/A	Shirley Ryan AbilityLab	2 mi
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues	Early 1	University of Chicago	2 mi
Web Intervention for Parents of Youth With Genetic Syndromes (WINGS)	N/A	Rush University Medical Center	2 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis	Phase 3	Celgene	2 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis	Phase 2	Novartis Pharmaceuticals	2 mi
Examining the Effects of a Remotely-delivered, Racially-tailored Exercise Training Program for Immediate and Sustained Improvements in Walking Dysfunction, Symptoms, and Health-related Quality of Life (HRQOL) Among African-Americans With Multiple Sclerosis (MS) Residing in Rural Environments.	N/A	University of Illinois at Chicago	2 mi
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists	—	Northwestern University	2 mi
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer	Phase 1	National Cancer Institute (NCI)	2 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	2 mi
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis	Phase 3	Sanofi	12 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)	Phase 3	National Institute of Allergy and Infectious Diseases (NIAID)	12 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease	—	TScan Therapeutics, Inc.	12 mi
Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis	Phase 3	Immunic AG	20 mi
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	Phase 2	Eli Lilly and Company	20 mi
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis	Phase 4	Novartis Pharmaceuticals	27 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.